CO5170416A1 - Derivados de 4,4-biarilpiperidina - Google Patents
Derivados de 4,4-biarilpiperidinaInfo
- Publication number
- CO5170416A1 CO5170416A1 CO99057228A CO99057228A CO5170416A1 CO 5170416 A1 CO5170416 A1 CO 5170416A1 CO 99057228 A CO99057228 A CO 99057228A CO 99057228 A CO99057228 A CO 99057228A CO 5170416 A1 CO5170416 A1 CO 5170416A1
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- heteroaryl
- heterocycle
- aryl
- optionally substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Addiction (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Un compuesto de fórmula I<EMI FILE="99057228_1" ID="1" IMF=JPEG >R1 es hidrógeno, (alcoxi C0-C8)-(alquilo C0-C8)-, donde el número total de átomos de carbono es ocho o inferior, aril, aril-(alquilo C1-C8)-, heteroarilo, heteroaril-(alquilo C1-C8)-, heterociclo, heterociclo-(alquilo C1-C8), cicloalquilo C3-C7- o (cicloalquil C3-C7)-(alquilo C1-C8), donde dicho arilo y el resto arilo de dicho aril-(alquilo C1-C8) se seleccionan independientemente, de fenilo y naftilo y donde dicho heteroarilo y el resto heteroarilo de dicho heteroaril-(alquilo C1-C8)- se seleccionan independientemente de pirazinilo, benzofuranilo, quinolilo, isoquinolilo, benzotienilo, isobenzofurilo, pirazolilo, indolilo, isoindolilo, bencimidazolilo, purinilo, carbazolilo, 1,2,5-tiadiazolilo, quinazolinilo, piridazinilo, pirazinilo, cinolinilo, ftalazinilo, quinoxalinilo, xantinilo, hipoxantinilo, pteridinilo, 5-azacitidinilo, 5-azauracililo, triazolopiridinilo, imidazolopiridinilo, pirrolopirimidinilo, pirazolopirimidinilo, oxazolilo, oxadiazolilo, isoxazolilo, tiazolilo, isotiazolilo, furanilo, pirazolilo, pirrolilo, tetrazolilo, triazolilo, tienilo, imidazolilo, piridinilo y pirimidinilo; y donde dicho heterociclo y el resto heterocíclico de dicho heterociclo-(alquilo C1-C8)- se seleccionan de sistemas de anillo monocíclicos o bicíclicos no aromáticos saturados o insaturados, conteniendo dichos sistemas de anillo de cuatro a siete átomos de carbono en el anillo, uno a tres de los cuales puede estar opcionalmente reemplazado por O, N o S, y conteniendo dichos sistemas de anillo bicíclicos de siete a doce átomos de carbono en el anillo, de los cuales de uno a cuatro pueden estar opcionalmente reemplazados por O, N o S; y donde cualquiera de los restos arilo, heteroarilo o heterociclo de R1 puede estar opcionalmente sustituido por uno a tres sustituyentes, preferiblemente con uno o dos sustituyentes, seleccionados independientemente de halo (es decir, cloro, fluoro, bromo o yodo), alquilo C1-C6 opcionalmente sustituido por uno a siete (preferiblemente con cero a cuatro) átomos de flúor, fenilo, bencilo, hidroxi, acetilo, amino, ciano, nitro, alcoxi C1-C6, (alquil C1-C6)amino y [(alquil C1-C6)]2amino, y donde cualquiera de los restos alquilo de R1 (por ejemplo los restos alquilo de grupos alquilo, alcoxi o alquilamino) pueden estar opcionalmente sustituidos por uno a siete (preferiblemente por cero a cuatro) átomos de flúor;R2 es hidrógeno, arilo, heteroarilo, heterociclo, SO2R4, COR4, CONR5R6, COOR4 o C(OH)R5R6, donde cada uno de R4, R5 y R6 se definen, independientemente, como se ha definido antes R1, o R5 y R6, junto con el carbono o - 2 -nitrógeno al que se encuentran unidos, forman un anillo saturado de tres a siete eslabones que contiene de cero a tres heteroátomos seleccionados, independientemente de O, N y S, y donde dicho arilo, heteroarilo y heterociclo se definen como se han definido tales términos en la definición de R1, y donde cualquiera de los restos arilo, heteroarilo y heterociclo de R2 puede estar opcionalmente sustituido con de uno a tres sustituyentes, preferiblemente con uno o dos sustituyentes, seleccionados independientemente de halo (es decir, cloro, fluoro, bromo o yodo), alquilo C1-C6 opcionalmente sustituido por uno a siete (preferiblemente con cero a cuatro) átomos de flúor, fenilo, bencilo, hidroxi, acetilo, amino, ciano, nitro, alcoxi C1-C6, opcionalmente sustituido por uno a siete (preferiblemente cero a cuatro) átomos de flúor, (alquil C1-C6)amino y [(alquil C1-C6)]2amino;R3 es hidroxi, NHSO2R7, C(OH)R7R8, flúor o CONHR7, donde R7 y R8 son iguales o distintos y se seleccionan de hidrógeno, alquilo C1-C4, alcoxi C1-C4 y (alcoxi C1-C4)-(alquilo C1-C4), que tienen un total de 4 o menos átomos de carbono, y donde cualquiera de los restos alquilo de R7 y R8 puede estar opcionalmente sustituido por uno a siete (preferiblemente de cero a cuatro) átomos de flúor; yZ1 y Z2 se seleccionan, independientemente, de hidrógeno, halo y alquilo C1-C5;con la condición de que no existen dos átomos de oxígeno de anillo adyacentes y no hay átomo de oxígeno adyacente a un átomo de nitrógeno de anillo o a un átomo de azufre de anillo en cualquiera de los restos heterociclo o heteroarilo de fórmula I;o una de las sales farmacéuticamente aceptables de dicho compuesto.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9956598P | 1998-09-09 | 1998-09-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5170416A1 true CO5170416A1 (es) | 2002-06-27 |
Family
ID=22275622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO99057228A CO5170416A1 (es) | 1998-09-09 | 1999-09-09 | Derivados de 4,4-biarilpiperidina |
Country Status (41)
| Country | Link |
|---|---|
| US (2) | US6720336B2 (es) |
| EP (1) | EP1112255B1 (es) |
| JP (1) | JP2002524445A (es) |
| KR (1) | KR20010075024A (es) |
| CN (1) | CN1316993A (es) |
| AP (1) | AP2001002088A0 (es) |
| AR (1) | AR022376A1 (es) |
| AT (1) | ATE312819T1 (es) |
| AU (1) | AU749096B2 (es) |
| BG (1) | BG105411A (es) |
| BR (1) | BR9913512A (es) |
| CA (1) | CA2343236C (es) |
| CO (1) | CO5170416A1 (es) |
| CZ (1) | CZ2001850A3 (es) |
| DE (1) | DE69928945T2 (es) |
| EA (1) | EA200100203A1 (es) |
| EE (1) | EE200100145A (es) |
| ES (1) | ES2252960T3 (es) |
| GE (1) | GEP20033025B (es) |
| GT (1) | GT199900146A (es) |
| HK (1) | HK1040396A1 (es) |
| HN (1) | HN1999000149A (es) |
| HR (1) | HRP20010167A2 (es) |
| HU (1) | HUP0103542A3 (es) |
| ID (1) | ID29129A (es) |
| IL (1) | IL141506A0 (es) |
| IS (1) | IS5860A (es) |
| MA (1) | MA26686A1 (es) |
| NO (1) | NO20011183L (es) |
| NZ (1) | NZ509841A (es) |
| OA (1) | OA11648A (es) |
| PA (1) | PA8481301A1 (es) |
| PE (1) | PE20001053A1 (es) |
| PL (1) | PL346648A1 (es) |
| SK (1) | SK3032001A3 (es) |
| SV (1) | SV1999000147A (es) |
| TN (1) | TNSN99169A1 (es) |
| TR (1) | TR200100694T2 (es) |
| WO (1) | WO2000014066A1 (es) |
| YU (1) | YU11501A (es) |
| ZA (1) | ZA200101744B (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030158220A1 (en) * | 1997-11-03 | 2003-08-21 | Foss Joseph F. | Use of methylnaltrexone and related compounds to treat chronic opioid use side effects |
| EP1038872A1 (en) * | 1999-02-22 | 2000-09-27 | Pfizer Products Inc. | 4-Phenyl-4-heteroarylpiperdine derivatives as opioid receptor ligands |
| SE9902765D0 (sv) * | 1999-07-21 | 1999-07-21 | Astra Pharma Prod | Novel compounds |
| US6974824B2 (en) * | 2001-01-08 | 2005-12-13 | Research Triangle Institute | Kappa opioid receptor ligands |
| EP1279666A1 (en) | 2001-07-24 | 2003-01-29 | Pfizer Products Inc. | 1-diphenylmethyl-pyrazole derivatives as opioid receptor ligands |
| MXPA04007719A (es) | 2002-02-07 | 2005-09-08 | Univ Missouri | Compuestos 4-(3hidroxifenil) o 4-(3-alcoxifenil)-1,2,4-triazol activos del receptor opioide. |
| SE0203302D0 (sv) * | 2002-11-07 | 2002-11-07 | Astrazeneca Ab | Novel Compounds |
| SE0203301D0 (sv) * | 2002-11-07 | 2002-11-07 | Astrazeneca Ab | Novel Compounds |
| CA2507465C (en) | 2002-11-26 | 2009-04-28 | Pfizer Products Inc. | Phenyl substituted piperidine compounds for use as ppar activators |
| CN104383542B (zh) | 2003-04-08 | 2017-09-26 | 普罗热尼奇制药公司 | 包含甲基纳曲酮的药物配方 |
| CL2004000754A1 (es) * | 2003-04-11 | 2005-02-25 | Janssen Pharmaceutica Nv | Uso de compuestos derivados de 4-fenil-4-(1h-imidazol-2-il)piperidina, como agonistas delta-opioides no peptidicos, para preparar un medicamento util en prevenir o tratar trastornos del sistema nervioso central. |
| US20070078120A1 (en) * | 2003-10-21 | 2007-04-05 | Hitoshi Ban | Novel piperidine derivative |
| PL1706385T3 (pl) | 2003-12-23 | 2011-03-31 | Astex Therapeutics Ltd | Pochodne pirazolu jako modulatory kinazy białkowej |
| EP1584335A3 (en) * | 2004-04-05 | 2006-02-22 | Laboratorios Del Dr. Esteve, S.A. | Active substance combination comprising a carbinol composition and an opioid |
| US7872023B2 (en) * | 2005-02-17 | 2011-01-18 | Research Triangle Institute | Kappa opioid receptor ligands |
| MX2007010833A (es) * | 2005-03-07 | 2009-02-17 | Univ Chicago | Uso de antagonistas opioides para atenuar proliferacion y migracion de células endoteliales. |
| US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
| US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| US8524731B2 (en) * | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| AR057325A1 (es) * | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
| AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
| WO2006136823A1 (en) * | 2005-06-21 | 2006-12-28 | Astex Therapeutics Limited | Heterocyclic containing amines as kinase b inhibitors |
| JP2008546751A (ja) | 2005-06-22 | 2008-12-25 | アステックス・セラピューティクス・リミテッド | 医薬組成物 |
| JP5345842B2 (ja) | 2005-06-23 | 2013-11-20 | アステックス・セラピューティクス・リミテッド | プロテインキナーゼモジュレーターとしてのピラゾール誘導体を含む医薬組み合わせ |
| DE102005061427A1 (de) * | 2005-12-22 | 2007-06-28 | Grünenthal GmbH | Substituierte Oxadiazol-Derivate |
| TW200817048A (en) * | 2006-09-08 | 2008-04-16 | Wyeth Corp | Dry powder compound formulations and uses thereof |
| GB0704932D0 (en) | 2007-03-14 | 2007-04-25 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| PA8774201A1 (es) | 2007-03-29 | 2009-06-23 | Progenics Pharm Inc | Antagonista del receptor |
| MX351611B (es) | 2007-03-29 | 2017-10-20 | Wyeth Llc | Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas. |
| SI2139890T1 (sl) * | 2007-03-29 | 2014-12-31 | Wyeth Llc | Antagonisti perifernih opioidnih receptorjev in njih uporaba |
| EP2730578A1 (en) | 2008-02-06 | 2014-05-14 | Progenics Pharmaceuticals, Inc. | Preparation and use of (r),(r)-2,2'-bis-methylnal trexone |
| EP2278966B1 (en) * | 2008-03-21 | 2019-10-09 | The University of Chicago | Treatment with opioid antagonists and mtor inhibitors |
| CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
| EP2263664A1 (en) * | 2009-05-18 | 2010-12-22 | Nestec S.A. | Opioid receptors stimulating compounds (thymoquinone, Nigella sativa) and food allergy |
| EP3570838B1 (en) | 2017-01-17 | 2024-06-05 | Mebias Discovery, Inc. | Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same |
| BR112019018774A2 (pt) * | 2017-03-12 | 2020-04-07 | Wang Xiaodong | composto tendo uma estrutura de acordo com a fórmula i, sal farmaceuticamente aceitável, composição farmacêutica, método para prevenir ou tratar uma doença ou afeção e método para imunomodulação, inibição ou prevenção de rejeição de enxertos de órgãos ou pele ou tratamento de tumores ou câncer |
| US11584765B2 (en) | 2017-03-12 | 2023-02-21 | Ecstasy LLC | Polycyclic amines as sigma receptor modulators |
| US10172634B1 (en) * | 2017-10-16 | 2019-01-08 | Michael Bruce Horowitz | Catheter based retrieval device with proximal body having axial freedom of movement |
| AU2021300217A1 (en) | 2020-07-01 | 2023-02-02 | Ecstasy, LLC | Polycyclic amines for opioid receptor modulation |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1936452C3 (de) * | 1969-07-17 | 1975-06-19 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Verfahren zur Herstellung von 4,4-Diphenylpiperidlnen |
| US4016280A (en) | 1969-07-17 | 1977-04-05 | Byk Gulden Lomberg Chemische Fabrik Gmbh | 4,4-Diarylpiperidine compositions and use |
| DE2166997C3 (de) | 1971-08-04 | 1980-03-27 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Verfahren zur Herstellung von 4,4-Diphenyl-piperidinen |
| DE2139085C3 (de) * | 1971-08-04 | 1979-01-18 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Halogenierte 4,4-Diphenyl-piperidine, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel |
| DE2139084C3 (de) | 1971-08-04 | 1979-03-01 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Verfahren zur Herstellung von 4,4-Diphenyl-piperidinen |
| ES2066721B1 (es) * | 1993-05-18 | 1996-02-16 | Ferrer Int | Nuevos compuestos derivados de la piridina 1,4-disustituida. |
| US5434171A (en) * | 1993-12-08 | 1995-07-18 | Eli Lilly And Company | Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates |
| WO1996031208A2 (de) * | 1995-04-05 | 1996-10-10 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Verwendung von substituierten piperidin- oder pyrrolidinverbindungen zur behandlung von sigma-rezeptor modulierten krankheiten |
| WO1997042956A1 (en) | 1996-05-16 | 1997-11-20 | Synaptic Pharmaceutical Corporation | Didhydropyrimidines and uses thereof |
| CA2255727A1 (en) | 1996-05-31 | 1997-12-04 | Trophix Pharmaceuticals, Inc. | Pharmaceutical for treating of neurological and neuropsychiatric disorders |
-
1999
- 1999-09-01 HN HN1999000149A patent/HN1999000149A/es unknown
- 1999-09-03 GT GT199900146A patent/GT199900146A/es unknown
- 1999-09-06 AP APAP/P/2001/002088A patent/AP2001002088A0/en unknown
- 1999-09-06 JP JP2000568825A patent/JP2002524445A/ja active Pending
- 1999-09-06 EE EEP200100145A patent/EE200100145A/xx unknown
- 1999-09-06 ES ES99939576T patent/ES2252960T3/es not_active Expired - Lifetime
- 1999-09-06 NZ NZ509841A patent/NZ509841A/en unknown
- 1999-09-06 CN CN99810757A patent/CN1316993A/zh active Pending
- 1999-09-06 HU HU0103542A patent/HUP0103542A3/hu unknown
- 1999-09-06 KR KR1020017003088A patent/KR20010075024A/ko not_active Application Discontinuation
- 1999-09-06 OA OA1200100057A patent/OA11648A/en unknown
- 1999-09-06 BR BR9913512-4A patent/BR9913512A/pt not_active IP Right Cessation
- 1999-09-06 EA EA200100203A patent/EA200100203A1/ru unknown
- 1999-09-06 DE DE69928945T patent/DE69928945T2/de not_active Expired - Fee Related
- 1999-09-06 WO PCT/IB1999/001512 patent/WO2000014066A1/en not_active Application Discontinuation
- 1999-09-06 SK SK303-2001A patent/SK3032001A3/sk unknown
- 1999-09-06 TR TR2001/00694T patent/TR200100694T2/xx unknown
- 1999-09-06 EP EP99939576A patent/EP1112255B1/en not_active Expired - Lifetime
- 1999-09-06 CA CA002343236A patent/CA2343236C/en not_active Expired - Fee Related
- 1999-09-06 ID IDW20010549A patent/ID29129A/id unknown
- 1999-09-06 IL IL14150699A patent/IL141506A0/xx unknown
- 1999-09-06 PL PL99346648A patent/PL346648A1/xx not_active Application Discontinuation
- 1999-09-06 GE GEAP19995785A patent/GEP20033025B/en unknown
- 1999-09-06 CZ CZ2001850A patent/CZ2001850A3/cs unknown
- 1999-09-06 AT AT99939576T patent/ATE312819T1/de not_active IP Right Cessation
- 1999-09-06 AU AU53837/99A patent/AU749096B2/en not_active Ceased
- 1999-09-07 PE PE1999000898A patent/PE20001053A1/es not_active Application Discontinuation
- 1999-09-07 AR ARP990104494A patent/AR022376A1/es not_active Application Discontinuation
- 1999-09-08 MA MA25759A patent/MA26686A1/fr unknown
- 1999-09-08 SV SV1999000147A patent/SV1999000147A/es not_active Application Discontinuation
- 1999-09-08 TN TNTNSN99169A patent/TNSN99169A1/fr unknown
- 1999-09-08 PA PA19998481301A patent/PA8481301A1/es unknown
- 1999-09-09 CO CO99057228A patent/CO5170416A1/es not_active Application Discontinuation
- 1999-09-16 YU YU11501A patent/YU11501A/sh unknown
-
2001
- 2001-02-23 IS IS5860A patent/IS5860A/is unknown
- 2001-03-01 ZA ZA200101744A patent/ZA200101744B/en unknown
- 2001-03-08 HR HR20010167A patent/HRP20010167A2/hr not_active Application Discontinuation
- 2001-03-08 NO NO20011183A patent/NO20011183L/no not_active Application Discontinuation
- 2001-04-04 BG BG105411A patent/BG105411A/bg unknown
- 2001-07-10 US US09/901,825 patent/US6720336B2/en not_active Expired - Fee Related
-
2002
- 2002-03-07 HK HK02101744.5A patent/HK1040396A1/zh unknown
-
2003
- 2003-12-23 US US10/744,735 patent/US20040138220A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5170416A1 (es) | Derivados de 4,4-biarilpiperidina | |
| CO5290258A1 (es) | Derivados de fenilheteroalquilaminas, proceso para su prepracion y composiciones farmaceuticas que contienen dichos derivados | |
| AR038868A1 (es) | Derivados de 1-(2-aminoacetil)2-pirrolidincarbonitrilo, su uso para la preparacion de una formulacion farmaceutica, las formulaciones farmaceuticas que los contienen, un procedimiento para la preparacion de estos derivados, y los intermediarios y su uso en dicho procedimiento de preparacion | |
| RS50260B (sr) | Imidazoimidazoli i triazoli kao anti-inflamatorna sredstva | |
| RU95113086A (ru) | Производные 5-членного гетероарилоксазолиндинона в виде смеси изомеров или отдельных изомеров, их соли и s-оксиды, а также фармацевтическая композиция с антибактериальной активностью на их основе | |
| CO5550444A2 (es) | Pirazolpirimidinas como agentes terapeuticos | |
| ES2196772T3 (es) | Compuestos amino ciclicos. | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| ES2190221T3 (es) | Derivados de indol y su uso para el tratamiento de enfermedades malignas y otras, que se basan en proliferaciones celulares patologicas. | |
| FR2658511B1 (fr) | Nouveaux derives de benzimidazole et d'azabenzimidazole, antagonistes des recepteurs au thromboxane; leurs procedes de preparation, compositions pharmaceutiques les contenant. | |
| NO990472L (no) | Fluorholdige 1,4-disubstituerte piperidinderivater | |
| RU2018121834A (ru) | Новое соединение бифенила или его соль | |
| CO5271670A1 (es) | Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas | |
| AR036107A1 (es) | Derivados de 6-fenilpirrolpirimidindiona, antagonista de los receptores a2 de la adenosina, particularmente del subtipo a2, de aplicacion en la prevencion de la degranulacion de los mastocitos; composiciones farmaceuticas formuladas con dichos compuestos y uso de los mismos en la preparacion de medi | |
| ES2183548T3 (es) | Dihidropirimidinas. | |
| ES2126573T3 (es) | Derivado de pirazol (1,5-a)pirimidina y agente antiinflamatorio que contiene este derivado. | |
| AR008386A1 (es) | DERIVADOS DE BENZIMIDAZOL CON ACTIVIDAD ANTIHISTAMINICA Y COMPOSICIoN FARMACÉUTICA ANTIHISTAMINICA QUE LOS CONTIENE. | |
| DE69229874D1 (de) | Pyrido pyridazinon und pyridazinthionverbindungen mit pde iv inhibierender wirkung | |
| GT200000145A (es) | Procedimiento para la obtencion de los inhibidores triciclicos de poli (adp-ribosa) polimerasas. | |
| AR032436A1 (es) | Oxazolidinonas substituidas, procedimiento para su preparacion, medicamentos, el uso de las mismas para la fabricacion de medicamentos, y el metodo para impedir la coagulacion sanguinea in vitro | |
| CO5640084A2 (es) | Ligandos de receptores cannabinoides y sus usos | |
| NZ512731A (en) | Tricyclic inhibitors of poly(ADP-ribose) polymerases | |
| AR069843A1 (es) | Derivados de piridazinona, procedimiento para preparar dichos compuestos, composiciones farmaceuticas y usos de los mismos para preparar un medicamento | |
| JP2010524947A5 (es) | ||
| CO5140110A1 (es) | Nuevos antibioticos macrolidos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |